Viveve Medical, Inc.

Good afternoon and welcome to the VIVI First Quarter 2021 Financial Results and Corporate Update Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's prepared remarks, there will be a brief question and answer session. Please note this event is being recorded. I will now turn the call over to Jeannie Swindle, the Senior Director of Corporate Communications. Please go ahead.

Thank you, Operator, and welcome, everyone. Before we begin, we would like to remind you that this conference call may contain forward-looking statements regarding future events or the future financial performance of the company. Any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the corporation's projections, expectations, plans, beliefs, and prospects. These statements are based on judgments and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statement. These risks and uncertainties are described more fully in the company's annual report on Form 10-K and other filings made with the SEC, which are also available on the company's website. Also, any forward-looking statements represent management's view only as of the date of this conference call and should not be relied upon as representing management's views as of any subsequent date. Speaking on today's call will be Scott Durbin, LV's Chief Executive Officer, and Jim Robbins, Senior Vice President of Finance and Administration. I will now turn the call over to Jim.

Thank you, Jeannie. Good afternoon, everyone, and thank you for joining the call today. I will begin today's call with a brief review of our first quarter 2021 financial results. I will then turn the call over to Scott, who will provide a corporate update, and afterwards, we'll open the call to questions. Today, we reported total revenue for the first quarter of $1.5 million from the global sale of eight of these systems and approximately 2,450 consumable treatment tips. As of the end of the first quarter 2021, the company had an installed base of 860 VIV systems worldwide. Total operating expenses for the first quarter decreased to $5.5 million, a reduction from $6 million for the same period last year. The decrease is a result of the company's organizational realignment to focus on our current SUI clinical development program. We ended the quarter in a strong cash position due to the success of our public offering in January, and our lowered operating cash burn at $3.3 million in Q1. Cash and cash equivalents as of March 31st were $28.4 million. Before handing the call to Scott, I will remind Vaviv shareholders on our call this afternoon that Vaviv's recent 2021 Annual Stockholders Meeting was adjourned to June 2nd due to a lack of quorum. We would like to encourage all shareholders of record to please vote. Thanks. I'll now turn the conference call over to Scott.